Enliven Therapeutics Inc.
$ 60.46
0.32%
07 Aug - close price
- Market Cap 4,429,950,000 USD
- Current Price $ 60.46
- High / Low $ 61.77 / 59.73
- Stock P/E N/A
- Book Value 7.45
- EPS -1.65
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.19 %
- ROE -0.27 %
- 52 Week High 62.32
- 52 Week Low 14.79
About
Enliven Therapeutics Inc. (Ticker: ELVN) is an innovative biotechnology company focused on transforming cancer therapies and addressing critical healthcare challenges through its proprietary therapeutic platforms. With a robust pipeline of advanced drug candidates developed using cutting-edge biopharmaceutical technologies, the company is dedicated to enhancing patient care and quality of life. Enliven's commitment to scientific excellence and its mission to fulfill unmet needs in oncology strategically position it for substantial shareholder value while making a meaningful contribution to the healthcare ecosystem.
Analyst Target Price
$71.11
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-07 | 2026-03-03 | 2025-11-12 | 2025-08-13 | 2025-05-14 | 2025-03-13 | 2024-11-13 | 2024-08-13 | 2024-05-14 | 2024-03-14 | 2023-11-09 |
| Reported EPS | -0.49 | -0.38 | -0.48 | -0.32 | -0.49 | -0.57 | -0.46 | -0.48 | -0.41 | -0.54 | -0.47 | -0.51 |
| Estimated EPS | -0.38 | -0.41 | -0.3778 | -0.46 | -0.42 | -0.5 | -0.5175 | -0.5 | -0.56 | -0.57 | -0.54 | -0.47 |
| Surprise | -0.11 | 0.03 | -0.1022 | 0.14 | -0.07 | -0.07 | 0.0575 | 0.02 | 0.15 | 0.03 | 0.07 | -0.04 |
| Surprise Percentage | -28.9474% | 7.3171% | -27.0513% | 30.4348% | -16.6667% | -14% | 11.1111% | 4% | 26.7857% | 5.2632% | 12.963% | -8.5106% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ELVN
2026-08-08 03:42:07
LifeSci Capital has reiterated its Buy rating for Enliven Therapeutics (ELVN.US) and increased its target price to $70. This updated target price indicates a strong positive outlook from the firm regarding the company's future performance.
2026-08-07 02:40:54
Enliven Therapeutics director Mika Derynck sold 158,795 shares of company stock for approximately $9.
2026-08-07 02:40:54
Enliven Therapeutics director Mika K. Derynck exercised stock options for 158,795 shares on August 4, 2026, at various exercise prices, then sold all 158,795 shares at a weighted average price of $60.2134 per share. These transactions were conducted as part of a Rule 10b5-1 trading plan adopted in April 2025, with all options being fully vested and exercisable. The total gross sale proceeds were approximately $9.56 million, resulting in an approximate pre-tax spread of $7.84 million.
2026-08-06 14:40:54
Guggenheim has reduced its target price for Enliven Therapeutics, Inc. (ELVN.O) from $80 to $78. This financial adjustment was reported by Reuters. The article itself is a brief news update, with no further details provided regarding the reasons for the target price cut.
2026-08-06 14:40:54
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G/A, disclosing a 15.0% beneficial ownership stake in Enliven Therapeutics Inc. (ELVN). This ownership amounts to 10,713,540.41 shares of common stock, with FMR LLC holding sole voting power over 10,704,808 shares and both FMR LLC and Abigail Johnson having sole dispositive power over all reported shares. The filing indicates that this investment is for ordinary course of business purposes and not intended to influence control of the issuer.
2026-08-06 13:42:07
Jefferies has increased its target price for Enliven Therapeutics, Inc. (ELVN.O) to $69 from the previous $59. This adjustment indicates a positive outlook from the investment bank on the company's future performance. The article, sourced from Reuters, provides no further details on the rationale behind the price target change.
